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"But, Mousie, thou art no thy-lane, 
In proving foresight may be vain; 
The best-laid schemes o' mice an' men 
Gang aft agley, 
An' lea'e us nought but grief an' pain, 
For promis'd joy!" 
 
Robert Burns  
(To a Mouse) 








POPULAR SCIENCE SUMMARY OF THE THESIS 
This doctoral thesis studies two diseases affecting the lung, more precisely sarcoidosis and 
idiopathic pulmonary fibrosis (IPF). Both diseases affect the lung tissue and can present with 
similar symptoms and findings. Sarcoidosis could be transient, but most develop a chronic 
disease; IPF is always chronic as well as fatal.  
Despite great scientific effort, the role of the immune system in sarcoidosis and IPF remains 
elusive. In this thesis we approach the phenomenon where the patients' immune system 
attacks their own tissues or cells, known as autoimmunity, as possible marker for disease. 
The overall aim is to find and characterize autoantibodies and antigens that can be related 
to autoimmunity or function as a marker for disease. 
We mainly use patient samples from the lung or blood in our analyses. The lung samples are 
collected through a procedure called bronchoalveolar lavage (BAL) where a flexible 
instrument access the patients' airways and instils physiological salt solution which is then 
recollected, blood is taken by conventional venous sampling via the arm of the patient.  
In several of our studies we use the powerful high-throughput method of multiplex 
suspension bead array (mSBA) to analyze our samples. The method uses microscopic colour 
coded beads and the use of antibodies/proteins to detect its counterpart.  
In the first project we investigate samples from the lung, bronchoalveolar lavage (BAL) and 
blood from sarcoidosis patients in order to characterize the presence of inflammatory 
proteins. These results are then compared with healthy controls and other inflammatory 
diseases, such as asthma, to look at differences between what is healthy and what can be 
associated with disease. Two proteins (Fibronectin 1 and C-C motif chemokine 2) stood out 




In the second project we used lung and blood samples to search for self recognizing 
(autoimmune) antibodies with the help of the mSBA method. By utilizing the Human Atlas 
Project, a large library of antibodies and proteins fragments, we were able to investigate 
virtually any proteomic antigen target within the body. We discovered four targets 
displaying autoreactivity in lung and blood samples from sarcoidosis patients compared to 
healthy controls, especially antibodies towards the proteins Zinc finger 688 (ZNF688) and 
Adenosine diphosphate-ribosylation factor GTPase activating protein 1 (ARFGAP1) showed 
significantly higher reactivity frequency in sarcoidosis than in control samples.  
In order to further understand the range of function for antibodies we investigated 
variations in the sugar structures (glycosylation) of the so called constant part of the 
antibodies, both in blood and lung samples. These structures are known to change in 
different inflammatory diseases, and a way of assessing the state of inflammation in the 
airways through a blood sample would be of great benefit to the clinic. We identified a 
potential marker for chronic inflammation in the lung by using the ratio between two 
different types of glycosylation structures in a subset of antibodies; the marker was able to 
separate different lung diseases to each other as well as healthy controls. This marker can 
thus be easily accessed through a regular venous blood sample, while still estimate the 
extent of inflammation in the airways. 
Together with collaborators in France and Netherlands we put together a large number of 
samples from IPF patients; we aimed to characterize the self-recognizing (autoimmune) 
antibodies in lung samples and blood and compare IPF patients to sarcoidosis. Targets 
recognized by the autoantibodies (autoantigens) were found in a majority of samples, 
including healthy controls, although the healthy controls had in general a lower presence of 
autoreactivity and also relatively lower levels of antibodies. An antibody towards one type 
of collagen (collagen 5 A1) stood out with higher presence in IPF and nLS. Altogether, 
autoreactivity was higher in IPF and in nLS patients compared to all other groups; interesting 
since both groups develop fibrosis at a higher rate than the other diseases. The protein 
epitope of COL5A1 is proposed as an autoimmune target and/or marker of fibrosis, and is of 
interest for further investigation. 
Currently there are few options for sarcoidosis or IPF patients when it comes to tools for 
prognosis or disease specific treatment; this, together with diagnostic challenges, entails the 




We investigate Sarcoidosis and Idiopathic Pulmonary Fibrosis, IPF, to find markers for early 
fibrosis development. The aetiologies for both diseases are unknown and there is no specific 
treatment, moreover, there is a lack of diagnostic biomarkers for both diagnose and disease 
activity. Overall, the diseases have a considerable effect on patients’ physical health and 
quality of life. To identify patients at risk of rapid development of fibrosis, it is vital to 
improve patient care. We hypothesize that identification of specific antigens can help in the 
exposition of the pathogenesis of sarcoidosis as well as of IPF, and in the long perspective 
this could lead to identification of therapeutic targets. 
In project I we investigated the presence of proteins in BAL and serum from sarcoidosis 
patients and controls to discover disease associated proteins. In total eight proteins had 
increased levels in sarcoidosis patients, two were the most prominent (Fibronectin 1, FN1 
and C-C motif chemokine 2, CCL2) that displayed the greatest differences between cohorts. 
Furthermore, the protein cadherin 5 (CDH5) had a positive association to lymphocyte count 
in BAL, interesting since T-lymphocytes are the major cell type in sarcoidosis. Potentially this 
could provide a way of monitoring lymphocyte presence in the lung through blood sample. 
In project II the large source of antigens from the Human Protein Atlas Project, a large 
library of protein fragments and antibodies that represent virtually all proteins in the body, 
was used to screen the immunoglobulin G specificity towards 3072 selected antigens in 
serum and BAL samples from patients with either of the sarcoidosis subcategories (Löfgren's 
syndrome (LS), non-Löfgren's sarcoidosis (nLS)), and asthma as well as healthy controls. A 
selected set of antigens went on to be analyzed in mSBA analysis. Sarcoidosis patients 
demonstrated an elevated reactivity frequencies toward Zinc finger protein 688 (ZNF688) 
and mitochondrial ribosomal protein L43 (MRPL43), particularly MRLP43 displayed a higher 
frequency in patients with non-Löfgren syndrome. Even though the protein fragment 
representing adenosine diphosphate-ribosylation factor GTPase activating protein 1 
(ARFGAP1) showed high reactivity frequency in all sample groups, it was still significantly 





In project III we used a mass spectrometry-based method to analyze and characterize the Fc 
regions of human IgGs in paired serum and BAL fluid. Antibodies were isolated using a fast 
and reliable approach via MelonGel extraction. The isolated IgGs were digested by trypsin 
and separated by nLC (nano liquid chromatography) as in conventional proteomics, but 
peptide fragmentation was performed by both high resolution HCD MS/MS (Higher-energy 
C-trap dissociation) and high-resolution ETD MS/MS (Electron-transfer dissociation). 
We identified a candidate marker IgG4, which corresponded well to inflammatory activity in 
chronic lung diseases while also correlating between BAL and serum (R2=0.95), thus being 
readily available for sample collection. The IgG galactosylation marker could prove to be 
useful in clinical settings by monitoring chronic pulmonary inflammation status. Based on 
the results of project II we concluded that the Fc galactosylation status of IgG4 could 
potentially be used as a serum marker for severity in pulmonary inflammation.  
In project IV project, we used the mSBA approach for both sarcoidosis and IPF samples in 
order to evaluate similarities and differences between fibrosis associated diseases. 
Autoantigens were found in a majority of patient samples, including healthy controls, 
although that cohort displayed a lower frequency of autoreactivity and also comparatively 
lower titers. Altogether, autoreactivity was higher in IPF and in nLS patients compared to all 
other groups; both groups included a higher fibrosis rate than the other diseases potentially 
linking a general presence of autoreactive antibodies to fibrosis development. Reactivity 
toward collagen 5A1 (COL5A1) was discovered with a statistical significant higher frequency 
in patients with IPF compared to all other groups apart from the nLS group. The protein 
epitope of COL5A1 is proposed as an autoimmune target and/or marker of fibrosis, and is of 
interest for further investigation.   
In this thesis we have profiled the repertoire of proteins and autoantibodies in serum and 
BAL from patients with sarcoidosis, in addition we also investigated and compared the 
presence of autoreactive antibodies in patients with sarcoidosis and IPF, as well as control 
subjects and various comparable diseases. We have also proposed the ratio between 
agalactosylated and galactosylated forms of the Fc region in IgG4 as a marker for severe 
chronic lung disease.  These discoveries open up for more studies to characterize, and test 
functionality, of these autoantibodies and proteins in the setting of sarcoidosis, IPF, or 
inflammatory and/or pulmonary diseases.  
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Ab Antibody 
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1 INTRODUCTION 
Sarcoidosis is an inflammatory granulomatous disorder primarily affecting the lungs, though 
virtually any organ may be affected. Patients usually suffer from cough, chest discomfort or 
pain, shortness of breath and a prominent fatigue. In Sweden, approximately one third of 
the patients develop an acute disease that, while more rapid, has a higher frequency of 
remission (Löfgren's syndrome), whereas others develop a chronic disease with possible 
fibrosis (non-Löfgren's sarcoidosis) (1, 2). Over time, especially in patients with long term 
treatment, sarcoidosis has an extensive impact on the patients' wellbeing and life quality.  
Just as sarcoidosis, Idiopathic pulmonary fibrosis (IPF) also belongs to the group of 
interstitial pneumonias, IPF is a chronic disease characterized by continuous fibrotic scarring 
of the lungs (3). IPF is progressive and first and foremost affects older adults, moreover IPF 
lead to a steady deterioration in lung function causing severe impairment of quality of life 
and is ultimately fatal within 2-5 years for those affected (3, 4). For both diseases the 
aetiology is unknown and there is no curative treatment. Moreover, there is a lack of 
disease markers to facilitate diagnosis and to assess disease activity, as well as to evaluate 
how patients respond to treatment.  
By running samples from both sarcoidosis, IPF, healthy and control diseases we gathered a 
repertoire of autoantibodies to be used as interesting targets for further functional studies. 
Furthermore, the antibodies or corresponding antigens in question could be used in the 
clinic as a marker for IPF or sarcoidosis in diagnosis or as a prognostic marker provided 
further research connecting these findings to disease outcome. All of this would hold great 
significance for research in interstitial lung diseases as well as the patients suffering from it. 
Potential biomarkers would help physicians diagnose the disease in an earlier state as well 
as provide drug targets in aid of treating patients (3, 4). In the short term this will give a 
broader understanding on how IPF and sarcoidosis patients differ in their immune status 
from healthy and other inflammatory diseases. The aim in the long term for this study is to 
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2 BACKGROUND 
2.1 THE RESPIRATORY SYSTEM 
The primary function of the respiratory system is to manage the gas exchange between 
inhaled air and the circulatory system. Within the pulmonary tissue, oxygen and carbon 
dioxide exchange by passive diffusion over a concentration gradient through the thin cell 
layers between the capillaries and alveoli (5). The respiratory system comprise of the 
conducting portion, where no gas exchange occurs, and the distal respiratory tract through 
which respiration transpires (6). The conducting portion begins with the nasal cavity, going 
through trachea and bronchus to terminal bronchioles, after which the distal portion starts 
with respiratory bronchioles and ends in the sacs of the alveoli. Throughout the respiratory 
system the airways go through numerous bifurcations, decreasing airway size but increasing 
the total surface area, which is an important aspect in order to amplify the surface for gas 
exchange (6). The globus structure and great number of alveoli represents a vast area 
upwards to 100 m2, consequently, the respiratory system presents one of the body’s largest 
surface areas, and is in direct contact with an outside world of potentially harmful agents, 
microorganisms and pollutants etc. (7). The respiratory epithelium is crucial in the defense 
against pathogens, using the aid of mucous producing goblet cells and ciliated lining to expel 
pathogens from the airways (5). In addition to its mucociliary functions, the epithelium 
possesses the ability to mount an immunological response. When exposed to harmful 
substances, the epithelial cells lining the airways can trigger immune cells, as well as 
produce proinflammatory cytokines and chemokines (8-10).  
Underneath the epithelial lining lies the interstitium, the space between cells, consisting of 
collagen I, III, and V entwined with elastin, glucosaminoglycans and proteoclycans to form a 
reticulate pattern (11). Its function is to support the surrounding tissue through transport of 
constituents and nutrients as well as for antigens and cytokines contributing in 
immunological responses (12). This interstitial space is frequently the location for some of 
the potentially difficult and debilitating pulmonary diseases, such as sarcoidosis and IPF (13, 
14).    





3 INNATE AND ADAPTIVE IMMUNE RESPONSE 
The immunological defense is stratified into two subcategories, the innate and adaptive 
immune response (Figure 1). The innate is congenital and represents a fast response 
against common and shared structures between microbes such as pathogen-associated 
molecular patterns (PAMP) and damage-associated molecular pattern (DAMP) (5). It is a 
highly conserved function, common throughout many species and organisms (15, 16). 
In contrast, the adaptive system represents a slower but more specific response as well as 
the capacity of immunological memory. The adaptive immune response can be further 
divided into the cellular response and the humoral response (15). 
 
 
Figure 1. Overview of the immune system. Including the quicker but broader innate immunity and the slower 
but more specific adaptive immunity. C(x) - Complement, MAC - Membrane attack complex, MBP - Mannan-
binding protein /Classic/Alternative - Complement pathway. PRR - Pathogen recognizing receptor.  
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3.1 INNATE IMMUNITY 
The cells that make up the innate, also known as natural, immune system includes 
neutrophils and natural killer cells (NK-cells), granule releasing cells, for example 
eosinophils, basophils and mast cells as well as monocytes. Circulating monocytes can 
migrate into tissues can differentiate into tissue resident macrophages and dendritic cells 
(DCs) (15). Macrophages, neutrophils and NK-cells are phagocytic, able to engulf and 
degrade extracellular pathogens through phagocytosis. In contrast, dendritic cells are 
professional antigen presenting cells (APCs) whose function primarily is to present antigens 
to other leukocytes (5). Eosinophils, basophils and mast cells release antimicrobial 
constituents to incapacitate the pathogens (5). Macrophages and DCs together with 
migrating neutrophils are able to react to a harmful pathogen through recognizing PAMPs 
and DAMPs and subsequently release pro-inflammatory molecules. These molecules are 
known as interleukins (IL) 1, IL6, IL12 and tumor necrosis factor (TNF) to promote 
inflammation and recruit leukocytes (17-19). Pathogens invading directly into human cells, 
e.g. viruses, can be cleared by NK cells. The virus infected cells present viral antigens on the 
cell surface which can be detected by NK cells who in turn will release perforins which 
disrupts the cell membrane of the infected cells, causing apoptosis (20). 
Another crucial component of the innate immune system is the complement activation 
cascade (16). Through cleaving complement proteins, the activated forms of complement 
protein 3 and 5 (C3a and C5a) will release additional proinflammatory cytokines. Other 
complement proteins form the cylindrical membrane attack complex (MAC) which attacks 
pathogens cell membrane rupturing bacterial cell walls (21). The native form of complement 
protein 3, C3b, will attach to, and identify, pathogens to more readily facilitate phagocytosis 
by macrophages, in a process called opsonization (15). The complement system is constant 
and doesn’t change over a lifetime, it can however be activated by antibodies produced by 




3.2 ADAPTIVE IMMUNITY 
Where the innate system is general but quick in its response, the adaptive system is 
slower to initiate but rather more specific and potent. The main effector cells are the T- 
and B -lymphocytes and they are triggered by specific antigens corresponding to the 
individual cell’s antigen receptor. Through somatic recombination of the receptor gene 
segments, a countless diversity of receptor specificity can be produced (15).  
APCs, including DCs, macrophages and B-cells are the primary cell types that actively take up 
antigen, process it and present it on the cell surface, where it is recognized by antigen 
receptors on T-cells (TCR). The T-cells belong to the cellular, T-mediated, response, while the 
B-cells belong to the antibody/humoral response. The two types of lymphocytes have 
different actions although the fundamental function of developing antigen specificity and 
establishing memory is similar. An overview of the T-cell and B-cell interaction can be seen 
in figure 2. 
Naïve T-cells are produced in the thymus after which they circulate into lymph nodes 
awaiting activation through specific antigen recognition. T-cells interact with APCs through 
the TCR via the major histocompatibility complex (MHC) on the APC surface. MHC is present 
in most vertebrates; the human version of MHC is known as human leukocyte antigen (HLA) 
(15). The most common T-cell receptor is a heterodimer consisting of two chains (alpha and 
beta), and each chain is composed of a constant (C) and a variable (V) region, whereas the 
antigen binding site consists of V-alpha and V-beta segments (15, 21). TCRs only recognize 
short fragments of proteins, peptides, and only when presented by the HLA molecules [29]. 
To detect all peptide variants, the TCR needs to accommodate an equal number of variants; 
this is done through germline recombination of the V(D)J segments of the variable regions 
(23). The HLA consists of a receptor with an antigen peptide being presented in the groove 
of the receptor. Depending if the origin of the antigen is from within the APC (endogenic) or 
outside the APC (exogenic) the antigen will be presented on HLA class I or II, respectively 
(15), and interact with TCRs of CD4+ or CD8+ T cells, respectively. The need for both the HLA 
molecule and the antigen peptide to interact with the TCR prevents the TCR from reacting to 
free circulating antigens. APCs will, after antigen uptake, migrate to the closest draining 
lymph node where resident naïve CD4+ and CD8+ waits to be activated (24). To avoid 
immune responses towards self-antigens, all T-cells go through a stringent selection process 
during maturation. In addition, a co-stimulatory signal is required during antigen 
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presentation to complete the activation of T-cells (25). Co-stimulation acts through APC co-
stimulatory proteins CD80/CD86 interacting with the CD28 and/or CTLA4 co-receptor on the 
T-cell (26). Not until both signals are present will the T-cell undergo maturation and start 
producing IL-2 which promotes proliferation and clonal expansion (21). CD4+ cells will 
identify peptides from HLA class II and CD8+ will recognize peptides from HLA class I. 
Activated CD8+ T-cells are primarily cytotoxic and aimed at intracellular antigens, commonly 
virus-derived, meaning the host cell has been invaded by a pathogen (15). This causes the T-
cell to induce apoptosis of the infected cell through the release of granzymes into the cell 
via the perforin created at the receptor interaction, effectively eliminating the intracellular 
pathogen (27). Activated CD4+ T-cells (T-helper cells, Th-cells) release cytokines and 
chemokines to attract macrophages, activate cytotoxic T-cells and enhance antibody 
production by B-cells, basically their primary purpose in inflammation is to aid other cell 
types through cytokine release. T-cells, in particularly CD4+ positive cells, can be functionally 
divided into subsets, called Th1 and Th2 type. Th1 is directed towards intracellular 
pathogens by stimulating a cellular response and Th2 against extracellular through 
stimulation of the humoral response, over time, additional subsets have been uncovered, 
adding T-regulatory cells (Treg), Th17, Th9 and Th22 to the list (28).  
 
Figure 2. Schematic overview of Follicular CD4+ T cell interaction with B cells in the lymph node. 
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B-cells constitutes the other half of the adaptive immune system, in contrast to T-cells which 
in essence solely detects protein peptides, the B-cells can identify a large variety of antigenic 
structures e.g. proteins, lipids, polysaccharides and nucleic acids. The B-cells develop in the 
bone marrow where recombination of the b-cell receptor (BCR) genes takes place, a process 
similar to the TCR recombination. After BCR assembly in the bone marrow, each BCR being 
specific towards one antigen structure, the transitional B-cell will then exit the bone marrow 
to travel to the spleen to fully mature. The fully matured B-cell then acts as an APC, 
detecting pathogens through its specific BCR and presenting antigens on their HLA class II 
molecule (5). The B-cells resides within the peripheral lymphoid organs, commonly within 
the follicles of lymph nodes, there, the B-cell consume pathogens through phagocytosis 
which are presented on the MHC class II molecule as peptides. The B-cell then becomes 
activated if the peptide is in parallel recognized by a CD4+ T-cell through the TCR, in 
combination with a co-stimulatory signal by interaction of CD40 on the B-cell and CD40L on 
the T-cell (16). Subsequently, the T-cell will start to produce cytokines causing the activated 
B-cell to differentiate into a plasma cell, producing highly antigen specific soluble non-
membrane bound BCRs known as immunoglobulins or antibodies. After clearing the 
infection, a small number of B-cells will remain as memory cells, able to mount a much 
faster response in case of a re-infection (15). 
 
3.3 ANTIBODIES  
Immunoglobulins (Ig) are Y-shaped proteins, which exists either as a part of the BCR 
receptor facilitating antigen recognition or produced and secreted by plasma cells after B-
cell activation. The basic Ig unit constitutes of two identical heavy and light chains. The 
heavy chain is composed of one variable and three constant domains (IgE has four constant 
domains). The light chain is built of one variable and one constant domain. After enzymatic 
degradation the antibody is split in two parts. One part is called fragment antigen binding, 
(Fab), comprising the antigen binding site and the first constant domain. The second 
fragment, containing the constant domains two and three of the heavy chain make up the 
fragment crystallizable region (Fc) which interacts with the receiving cell through Fc 
receptors (15).  
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Figure 3. Antibody subsets. IgD, IgG, IgE, IgM, and IgA schematic representations. 
 
There are five classes of immunoglobulins (Ig); IgD, IgG, IgE, IgM and IgA each with its 
primary function (Figure 3). The IgM molecule is composed of a pentamer, and together 
with IgD produced by naïve B-cells acting in early stages of humoral immune responses to 
eliminate pathogens (15). The IgD can stimulate production and release of antimicrobial 
factors in basophils and mast cells (29). Through class switching, plasma cells are able to 
produce the other types of Ig’s, where IgG is the main isotype in the body, and is stratified 
into four subclasses named IgG 1-4. They are numbered in decreasing order of abundance, 
though their abundance does not reflect their effector functions nor their efficiency (30). 
The IgG molecule can exert its antimicrobial function in various ways, either through binding 
to the antigen/microbe, priming it for opsonization by macrophages, or binding and 
neutralizing toxins, or initiating antibody-dependent cellular cytotoxicity through NK-cells. 
The IgA exists either as a monomer or as a dimer; it resides primarily in mucosal tissue, e.g. 
the respiratory or intestinal tract as well as in saliva and tears, where it rapidly acts against 
toxins and microbes. The IgEs primary function is defense against helminths, however, it is 
also responsible for binding allergens and causing hypersensitivity through degranulation of 




In order for the IgG antibody to facilitate effector functions, it relies on being able to identify 
a specific antigen through its Fab region and subsequently connect to the effector cell via 
the Fc gamma receptors (FcγR). While immunological effector functions serves to act as 
regulators of immunological homeostasis, a dysregulation can facilitate both tolerance and 
increased risk of infection (31).  
Structural alterations through glycosylation of the Ig's Fc region can have great effect on the 
downstream immunological response (32, 33). Variation to the Fc glycan composition can 
direct the antibody's affinity towards type I or II Fc gamma receptors (FcγR) and thus shift 
the immunological response to either pro- or anti-inflammatory actions,  as well as elicit 
specific actions such as opsonization or complement activation (32, 33). Generally, a more 
compound Fc-region will be inclined towards an anti-inflammatory response, especially if it 
has a high fraction of galactosylated or sialylated glycans (33-36). Furthermore, Fc-glycan 
changes have been demonstrated to be a potential marker for inflammation as well as being 
altered in autoimmune and inflammatory disease (37-40).  
Alterations by galactosylation in the Fc region has been described extensively in context of 
autoimmunity (41-43), including the discovery of anti-citrullinated protein antibodies (ACPA) 
acquiring a proinflammatory Fc glycan phenotype before diagnosis in rheumatoid arthritis 
patients (44). In Figure 4 a representation of the IgG molecule and the position of the Fc 
glycans can be observed (A) including the glycan core structure with nomenclature 
suggested by Royle et  al (B) (45).   
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Figure 4. a) Graphic representation of the IgG molecule and subsequent position of the Fc glycan structures. b) 
A schematic of glycan formation with nomenclature suggested by Royle et al.  (45). The core Fc glycan structure 
consists of a heptasaccharide constituent (denoted as A2).  If the first saccharide unit is carries a fucose, the 
core Fc glycan is fucosylated (denoted as FA2). The core configuration can as well be bisected by an additional 
N-acetyl-glucosamine (GlcNAc (denoted as FA2B)). Additionally, the top glucosamine units can be lengthened 
with galactoses (FA2Gn, n=1 or 2) and the galactoses can be extended with sialic acids (FA2GnSn, n=1 or 2). 
Blue squares - GlcNAc, green circles - mannose, yellow circles - galactose (G), red triangle - fucose (F), purple 
diamonds - sialic acid (S). Adapted from (46). 
 
3.4 TOLERANCE AND AUTOREACTIVITY  
T- and B-cells go through a selection procedure while maturing in order to ensure they only 
act against potentially harmful external antigens and not towards self-antigens, this 
acceptance for “self” is known as central tolerance (15). The T-cells undergo positive and 
negative selection in the thymus while B-cells undertake a similar selection but in the bone 
marrow. The first control point is during generation of the TCR and BCR receptor, where 
inability to form a functioning receptor results in apoptosis. Next the T-cells are tried against 
affinity for the HLA complex, no recognition results in apoptosis due to that a nonfunctional 
receptor would be futile. A too strong affinity runs the risk of activation without the second 
co-stimulatory signal, yielding apoptosis through negative selection. Positive selection take 
place as the interaction between the T-cell and APC is identified with low affinity, yielding 
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APC survival signals (15). Note that only self-antigens (autoantigens) are tested in positive 
and negative selection since external potentially pathogenic peptides rarely occurs in the 
thymus (5). The explanation for solely low/moderate avidity T-cells surviving the selection 
process is that these cells could instead exhibit a high avidity for pathogenic peptides in the 
periphery (15). 
B-cells are positively selected on the presence of a functional BCR and not its specificity 
(unlike T-cells). Negative selection ensues when immature B-cells interact too strong with 
self-antigens, this leads either to change in receptor specificity (receptor editing) or 
apoptosis. Anergy develops if a B-lymphocyte recognizes an antigen but at low avidity or 
does not receive the second co-stimulatory signal, the B-cell will then be functionally 
impaired. Once a functional BCR has been produced, the immature B-lymphocyte only 
expresses IgM. In order to mature the B-cell must co-express IgD together with IgM; this is 
done through recombination and splicing of the heavy chain V(D)J segment. Maturation 
develop either in the bone marrow or the B-cell will migrate to the spleen (15). Though 
lymphocytes go through a stringent selection process, one study indicated that as many as 
1/5 of all circulating B cells were autoreactive, though not generating disease (47).  
Although the tolerance system is highly accomplished, it can still malfunction and when 
tolerance is lost it can lead to autoimmunity. The prevalence in Europe for autoimmune 
disorders is estimated to 5%, in general, women tend to be more often afflicted than men 
(48, 49). It is not known why certain individuals develop autoimmunity and not others, 
however, risk factors such as environment, smoking, infections and gender has been 
observed (50-53). A strong connection with HLA composition has also been demonstrated 
(42-47). Additionally, autoreactivity can be triggered during infections if the pathogen’s 
antigen exhibits similar or homologous structures as a self-peptide, a phenomenon known 
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3.5 PULMONARY IMMUNOLOGY 
In contrast to circulating leukocytes, where neutrophils are most abundant, the primary 
phagocytic cells present in bronchoalveolar lavage (BAL) fluid are alveolar macrophages 
(AM). In healthy individuals the respiratory leukocytes consists of up to 95% of AMs; 
lymphocytes constitutes between 1-10% and neutrophils only 1% (55). However, in the 
case of an infection neutrophils will migrate to, and accumulate within the lungs, by far 
outnumbering the AMs (56). The epithelium can also activate innate and adaptive immune 
responses through the release of cytokines and chemokines, including production of 
antimicrobial substances (10, 22). Apart from phagocytosis of hazardous particles, AMs 
can also release nitric oxide (NO), reactive oxygen species (ROS) and proteolytic enzymes 
to destroy and degrade the attacking pathogen (57). Additionally, AM together with 
dendritic cells (DCs) present antigens for T-cells in order to stimulate a T-cell response 
(58). 
In general the lungs are an exposed organ given its large surface area and almost 
unhindered direct contact with environmental surroundings. This infers the immune 
system to be alert, without going to excess. In fact, both immunological hyper- and hypo- 
responses can lead to pathological reactions in the airways, e.g. obstructive diseases such 
as asthma or chronic obstructive pulmonary disease (COPD). However, it is not just the 
airways that can be affected, the interstitial space is frequently the site for pathogenic 
conditions, often of a restrictive type, including; Sarcoidosis, chronic beryllium disease 
(CBD), idiopathic pulmonary fibrosis (IPF) and silicosis. These diseases risk the 
development of fibrosis, subsequently, leading to impaired gas diffusion and gas exchange 
(59, 60).   
 
3.6 COVID-19 
It has been virtually impossible not to been affected by the coronavirus disease 19 (COVID-
19) during the past year, thus the disease require attention in this thesis. There have been 
over 150 million cases and more than 3 million deaths as of beginning of May 2021 due to 
COVID-19 (61). The pandemic that started late 2019 and took off during the first half of 2020 
has greatly affected a significant portion of the world population, and has dramatically 
increased hospitalization due to pneumonia and respiratory failure (62). COVID-19 is caused 
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by the novel virus variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
with symptoms ranging from asymptomatic to life-threatening sepsis and respiratory failure, 
although, the majority of infections result in a mild disease (62). 
The SARS-CoV-2 virus enters targeted cells via binding to converting enzyme 2 (ACE2) 
receptor on the cell surface using the SARS-CoV-2's own surface protein spike (S), in order to 
infuse the cell with ribonucleic acid (RNA) for virus replication (63). The type 2 
transmembrane serine protease (TMPRSS2) facilitates the fusion to host cells by cleaving 
the ACE2 receptor and trigger the (S) protein; both ACE2 and TMPRSS2 are ubiquitously 
found on alveolar type II cells located in the airways SARS-CoV-2 virus (63-65).  
During the later phase of the infection the SARS-CoV-2 virus infect capillary endothelial cells 
causing and invasion of monocytes and neutrophils into the respiratory space, resulting in 
oedema consistent with early stage acute respiratory distress syndrome (ARDS), with the 
consequence of deteriorating oxygen exchange (66, 67).  
There have been concerns that patients suffering from interstitial diseases would fare worse 
than others, especially for patients on immunosuppressant drugs, e.g. certain sarcoidosis 
patients (68). A study used a self-reporting questionnaire did demonstrate an increase in 
COVID-19 infection for sarcoidosis patients compared to non-sarcoidosis (69). A review of 
the incidence and prevalence of COVID-19 for patients (including sarcoidosis patients) on 
immunosuppressant drugs  did not find increased prevalence for COVID-19 nor increased 
risk for life-threatening disease, though the data was limited (70, 71). There have also been 
ideas of antifibrotic therapies protecting IPF patients from COVID-19 as well as providing 
treatment for non-IPF patients suffering from post-COVID-19 pulmonary fibrosis (72). 
However, more studies are needed on the subject of interstitial lung disease and COVID-19, 
and considering both sarcoidosis and IPF are comparatively rare diseases there is a great risk 
of delay before substantial data could be acquired.  
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4 SARCOIDOSIS  
4.1 CLINICAL FEATURES 
Sarcoidosis is an inflammatory granulomatous disorder primarily affecting the lungs, though 
essentially any organ may be affected. Approximately two thirds of the patients develop a 
chronic disease with possible fibrosis development and a risk of suffering respiratory failure 
(73, 74). Deteriorating physical health and side effects from long term treatment impacts 
the life of sarcoidosis patients.  
Sarcoidosis has been suggested to be composed of several separate disease entities with 
distinct etiologies, but also with common inflammatory pathways, e.g. resulting in the 
typical granuloma formation (75). One group of patients that is now known to suffer from 
chronic beryllium disease (CBD), caused by exposure to beryllium, was commonly 
misdiagnosed as sarcoidosis because of the clinical resemblance of sarcoidosis, including 
granuloma formation (76-78). One distinct subgroup of sarcoidosis patients, i.e. Löfgren´s 
syndrome (LS), characterized by its clinical phenotype with acute onset, fever, erythema 
nodosum (EN),  bilateral ankle arthritis and bilateral hilar lymphadenopathy (BHL), could 
constitute a separate disease (79). Approximately one third of Swedish sarcoidosis patients 
have LS, which is an unusually large proportion from an international perspective (80). The 
nLS patient group, constituting the majority of patients, usually presents gradually and are 
linked to a more chronic disease course, more often with development of pulmonary 
fibrosis (81). In many of our studies we compare LS and nLS patients to identify markers for 
good prognosis (usually LS) or for a less favorable disease course (usually nLS).  
 
4.2 EPIDEMIOLOGY 
The incidence as well as prevalence of sarcoidosis varies extensively between different parts 
of the world, as well as ethnicity. The highest incidence can be observed in Scandinavia with 
11-24 cases per100.000/year (80, 82, 83), and African Americans with 18-71 cases per 
100,000/year (84-86). Incidence in Sweden was recently estimated to be 12 per 
100.000/year, and the prevalence to be 160 per 100.000 (80) Some variation can also be 
noted between sexes where 45-60 percent of sarcoidosis cases occurs in women (87). The 
age of onset is on average between 40-55 years for all patients combined, though a 
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difference between sexes can be observed where men peak 30-50 years  age and women 
between 50-60 years of age (80, 88, 89).  
Several risk factors for developing sarcoidosis have been proposed. The most prominent is 
genetic susceptibility through increased risk of developing sarcoidosis for people with 
certain variants of Human Leukocyte Antigen (HLA) molecule (90, 91). The risk is also 
increased if you have a family member with the disease, increasing the risk by 2-4 times (92, 
93). 
While smoking is a risk factor associated with many diseases in general, and lung diseases in 
particular, smoking has consistently been related to a lower risk for sarcoidosis (1). Even a 
study collecting smoking status before diagnosis (removing bias where patients stop 
smoking because of the disease), smoking demonstrated a 50% lower risk of developing 
sarcoidosis (1, 94). 
 
4.3 PATHOGENESIS 
The complete aetiology behind sarcoidosis is not known. Current hypothesis states that 
susceptible individuals are exposed to one or more unknown antigen which leads to an 
inflammatory reaction where the immune system is unable to clear the antigen and form 
the base of granuloma formation. Activated macrophages can turn into epithelioid 
multinucleated cells under the influence of the metabolic checkpoint kinase mechanistic 
target of rapamycin complex 1 (mTORC1) pathway (95). This leads to a granuloma 
formation that could either resolve or progress. In case of progression, the granuloma is 
incapable of degrading the antigen and the antigen is instead encapsulated within the 
granuloma which continues to grow and chronic disease is developed. The granuloma 
consists, apart from previous mentioned epithelioid cells, also vast number of 
lymphocytes surrounding the core (96). The lymphocytes consists mainly of CD4+ T cells, 
but also a small number of CD8+ T-cells and some B-ells (97). Furthermore, an increased 
production of reactive oxygen species (ROS) together with increased inflammatory signals 
and tissue damage can be observed in chronic sarcoidosis which is believed to be cause by 
malfunctioning phosphorylation of mitochondrial proteins (98). In comparison with 
healthy individuals, dendritic cells from sarcoidosis patients produced much higher levels 
of TNF-α, which would indicate a self sustaining mechanism of both dendritic cells, cell 
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migration and granuloma formation (98). Sarcoidosis granulomas are non-caseating, 
meaning they are non-necrotizing, which is the opposite from granulomas in tuberculosis 
where macrophages do go into necrosis. Interestingly, a link between tuberculosis, or 
other mycobacteria, and the sarcoidosis antigen has both been suspected and dismissed 
by researchers; however, still there is no definite answer (99-102). An overview of the 
proposed pathogenesis of sarcoidosis can be seen in figure 5. 
The CD4+T-cell subset is the most common cell type in sarcoidosis, they are essential for 
sarcoidosis progress and for granuloma formation. When stimulating the immune system 
T-lymphocytes are activated and start proliferating, primarily T-cells and macrophages in 
the alveoli which leads inflammation in the airways (1). Macrophages and dendritic cells at 
the site of inflammation secrete IL-12 and IL-18 which aids the T-cells in their 
differentiation and maturation. In turn, the activated T-cells release high levels of IL-2, 
IFNγ and TNF-α which promotes macrophage activation and T-cell survival (103). 
Furthermore, after stimulation with candidate antigens, activated T-cells manifest a Th1 
type of response by producing large quantities of IFNγ in vitro (104).   
The view on the role of activated lymphocytes presence in sarcoidosis patients has shifted 
over time, from solely CD4+Th1 type driven disease into a more complex view involving 
the Th17.1 phenotype. These cells are capable of producing large quantities of IFNγ, thus 
promoting an inflammatory process in the lungs. T helper cells differentiate into Th1 and 
cells producing IFNγ, i.e. Th17.1 effector cells, as well as Th17 cells (105-107). A majority of 
T-cells acquired from BAL expressed the unique Th1 transcription factor T-box 
transcription factor 21 (Tbet), although they were also found to co-express RAR-related 
orphan gamma receptor (RORγt) which is the transcription factor for Th17, indicating 






Figure 5. Overview of the pathogenesis of Sarcoidosis. An extracellular (auto)antigen in the lung triggers the 
activation of phagocytes such as dendritic cells (DC) and macrophages. If the phagocytes are unable to clear 
the antigen, they will instead encapsulate the antigen and a characteristic granuloma formation occurs. The 
antigen is presented to CD4+T-cells that recognize the peptide and respond with a variety of cytokines. CD4+ 
T-cells expressing HLA-DRB1*03 will present the antigen to B-cells resulting in antigen specific antibodies. 
With a coordinated T and B cell response, the granuloma can be resolved. Though in chronic stages the 
response is unable to resolve the granuloma and instead the granuloma progresses, resulting in chronic 
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Still, the main effector cell in sarcoidosis is CD4+ T-cell; in fact lymphocytosis above 25% in 
bronchoalveolar lavage and an increased ratio between CD4/CD8 above 3.5 associate with 
sarcoidosis and it constitutes one diagnostic indicator (108, 109). In addition, T cells 
expressing TCR Vα2.3 gene segment has been found more frequently in patients with the  
DRB1*03 allele, most commonly patients with Löfgren's syndrome(108).  
Moreover, the regulatory T-cells (Treg) are normally responsible for maintaining steady 
state in T-cell activity; however, in sarcoidosis there is an exaggerated T-cell activity which 
leads to the conclusion that the Treg response is impaired. Although, it is uncertain 
whether the insufficient activity is primary, or if it's secondary to prolonged antigenic 
stimulation (109-111).  
A cornerstone in the sarcoidosis pathophysiological hypothesis is the existence of a 
triggering factor, an antigen. Quite a few suggestions exist, ranging from mycobacterium 
to autoantigens (112-115). Notably, LS patients expressing DRB1*03 were found to display 
immune response following stimulation with the autoantigen Vimentin (115). In line with 
this, several other peptides derived from proteins like lysyl-tRNA synthetase and ATP 
synthase were found in BAL from in DRB1*03 positive sarcoidosis patients (116, 117). 
 
4.4 DIAGNOSIS AND TREATMENT 
Sarcoidosis is diagnosed through its most prominent trait which is non-necrotizing 
granuloma formation in the affected organ; histological verification together with clinical 
findings typical for sarcoidosis with the absence of other explanation is the basis for 
diagnosis. Other investigations such as chest radiograph, bronchoalveolar lavage (BAL), 
positron emitting computer tomography (PET-CT) and spirometry can aid in the assessment 
of the patient. If there is a case where histopathological sampling is not possible, diagnosis 
can be made on a combination of classic clinical features, laboratory results and chest 
radiographs. One such typical finding in BAL is increased accumulation of CD4+ cells in BAL, 
yielding an elevated CD4+/CD8+ ratio >3.5, which is especially accurate for patients with 
Löfgren syndrome (118-120). Since the lung is the most commonly involved organ, a chest 
radiograph is standard procedure which commonly shows bihilar lymphadenopathy w/o 
pulmonary infiltrates. The chest radiograph is also used for staging (I-IV). The staging ranges 
from mild infiltrates all the way to fulminate fibrosis (121). 
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Bronchoscopy and BAL is routinely performed in the clinical evaluation of patients with 
suspected sarcoidosis, regularly giving access to inflammatory cells and mediators to be 
used for studies of the local inflammatory process in the lungs. Also, biopsies are obtained 
to search for non-necrotizing granulomas in affected tissues, typical for (but not definitively 
proving) sarcoidosis.  
The aetiology is unknown and there is no specific treatment, current praxis uses oral 
corticosteroids first choice, adding/or substituting to methotrexate in patients with 
persistent infiltrates or severe pulmonary dysfunction (109, 122, 123). Though patients 
with Löfgren syndrome and the HLADRB1*03  (HLA- DR3) allele have a better outcome, 
with remission in 70–80% of the cases (2). Biological treatments such as Infliximab (anti-
TNF-α) has been tried in patients with severe disease where all other therapies have 
failed, in an effort to downregulate T-cell activity, though success rates are highly 
individual (124, 125). As stated earlier, there is a lack of disease markers to facilitate 
diagnosis and to assess disease activity, as well as to evaluate how patients respond to 
treatment.   
 
4.5 SARCOIDOSIS AND AUTOREACTIVITY 
Autoimmunity in sarcoidosis is currently one of the more prominent concepts; the idea is 
supported by strong associations between certain HLA variants and LS. Furthermore, for a 
small percentage of patients the disease can be relapsing, whether this is a re-infection, or 
an autoimmune burst of the disease is unknown (126, 127). There are several instances 
where immunological hyperactivity rather than a deficiency will yield sarcoidosis or 
sarcoidosis like disease. For example, HIV positive patients undergoing anti-retroviral 
treatment has been shown to risk developing sarcoidosis when CD4+ T-cell counts >200 
cells/µL (128). Also, some patients treated with IFNα e.g. due to chronic hepatitis C have 
been discovered to develop a sarcoidosis-like disease (129-131). These examples are not 
what you would typically expect to find in a disease maintained by an infection.  
RA patients have been demonstrated to have autoreactive antibodies towards a 
citrullinated variant of the vimentin protein, strongly associated with disease (132, 133). 
Moreover, antibodies against citrullinated vimentin have been demonstrated in the lungs 
prior to disease onset, suggesting disease initiation in the lungs (despite a different target 
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organ) (134). Vimentin peptide has been implicated as a possible autoantigen in 
sarcoidosis, i.e. sarcoidosis patients have been shown to have a higher frequency of 
antibodies against vimentin in BAL compared to controls (115). The same vimentin 
peptide has also been eluted from AMs at several occasions in BAL samples from 
sarcoidosis patients (74). 
Sarcoidosis is not contagious, not cured by antibiotics, and not re-activated upon long 
term immunosuppressive treatments like corticosteroids, methotrexate or anti-TNF-drugs, 
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5 IDIOPATHIC PULMONARY FIBROSIS 
5.1 CLINICAL FEATURES 
Idiopathic pulmonary fibrosis (IPF) belongs to the group of interstitial pneumonias; it is a 
chronic fibrotic disease characterized by continuous fibrotic scarring of the lungs (3). IPF is 
progressive and first and foremost affects older adults, moreover IPF lead to a steady 
deterioration in lung function causing severe impairment of quality of life and is ultimately 
fatal within 2-5 years for those affected (3, 4, 14). As the name suggests IPF is idiopathic, 
meaning its pathogenic cause remains unknown, furthermore, there is also limited 
knowledge of prognostic factors and effective treatments (135). 
 
5.2 PATHOGENESIS 
Throughout history IPF was considered a primarily inflammatory disease, and as such it was 
treated with corticosteroids. Over time it became more apparent that the antiinflammatory 
treatment did not improve the outcome for these patients, and eventually the concept of 
IPF being primarily an inflammatory disease was overturned (136). Furthermore, the 
standard treatment at the time with corticosteroids and azathioprine was shown not only to 
be ineffective but also increase the risk of death. 
The pathogenesis behind IPF is still not clear, current hypothesis involves a multifaceted 
etiology with several genetic and environmental risk factors causing multiple microinjuries 
to the epithelium of the airways (137, 138). These microinjuries will subsequently lead to 
aberrant wound healing and excessive fibroblast-myofibroblast foci resulting in extensive 
amounts of extracellular matrix and remodeling (137, 138). There are also indications that 
shortening of telomeres and dysfunction protein telomerase could play a part in IPF 
pathophysiology, especially in familial cases (139-141). A general overview of the proposed 




The cytokines MMP1 and MMP7 aids in the epithelial migration, in addition, in the IPF lung 
the epithelial cells are highly active and produce growth factors and chemokines as well as 
stimulate fibroblasts the lungs (137). The epithelial cells also secrete TGFβ1, which is 
considered one of the key cytokines behind the IPF pathology. TGFβ1 stimulate extra 
cellular matrix production and help fibroblasts differentiate to myofibroblasts (138).  
Together, these cells form the fibroblast foci, in the foci the myofibroblasts are thought to 
be active in producing excessive quantities of ECM (138).   
 
 
Figure 6. General overview of the IPF pathogenesis.  The initiation of IPF is distinguished by both a genetic 
susceptibility to form progressive fibrosis together with several environmental triggers that can cause injury. 
Many risk factors have been indentified, smoking and aging being the two most prominent. When injuries have 
been sustained over time, an abnormal repair process occurs, with re-epithelialisation, migration of fibroblasts 
and the formation of collagen matrix. The progression results en excessive matrix formation which results in 
deformation of the airway structure and a steady decline in gas exchange. ECM - Extracellular matrix.  
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5.3 EPIDEMIOLOGY 
The incidence for IPF seems to be on the rise, although there is some uncertainty if the 
increase is real or due to more awareness and better diagnostics (138). Additionally, 
incidence is higher in North America and Europe (3-18 cases per 100,000/year) compared to 
other parts of the world such as Asia and South America (under 4 cases per 100,000/year) 
(4, 142-144). IPF occurs more often in older adults, usually over the age of 70, it is rare that 
people under the age of 50 get the disease. 
As stated earlier, several risk factors are believed to be contributing to the pathogenesis of 
IPF. Inhalation of particles, and more specific, cigarette smoke is strongly associated with 
the disease (145). Though, inhalation of other particles such as viruses, wood dust, silica and 
exposure to agriculture is believed to increase the risk of IPF (146-148).  
 
5.4 DIAGNOSIS AND TREATMENT 
Diagnosis of IPF is made on radiographic or histological foundation where pattern of Usual 
Interstitial Pneumonia (UIP) is one criterion (146, 149, 150). Patients routinely undergo High 
Resolution Computer Tomography (HRCT) where the UIP pattern can be observed. The 
same nomenclature is used for the histopathological image, though not the same criteria as 
for HRCT (151). Pulmonary fibrosis is the main feature of IPF, but since other diseases and 
drug side-effects are also able to yield fibrosis, a diagnosis of IPF is always in absence of 
other explanations. Because of this, it is recommended to diagnose IPF patients in 
multidisciplinary meetings to avoid missing any underlying cause (146). The classification of 
interstitial pneumonias has changed on several occasions, partly due to challenges with 
categorization; biomarkers would therefore be of big to help physicians diagnosing the 
disease in an early state (3, 4). 
In the later years IPF patients has had access to two new therapies, nintedanib and 
pirfenidone, both of which has demonstrated to have an effect in treating IPF (152). 
Primarily the drugs have had an effect on slowing the disease rate down, exhibited by 
holding back the decline in Forced Expiratory Volume (FVC) (153, 154). In addition, some 
data suggest a positive effect on acute exacerbations and hospitalization (155, 156).   
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5.5 INFLAMMATION AND AUTOREACTIVITY 
Even though IPF is not considered to be primarily an inflammatory disease, there is still a 
role to play for the immune system. Lymphocytes are found in the interstitium and fibrotic 
scars of IPF patients, as well as autoantibodies present in the serum which suggest a 
possible role for the immune system in either initiation or progression of IPF (142, 157). The 
tolerance loss in autoreactive T or B-cells to antigens resulting from debris of dying epithelial 
cells could drive the immunopathology of IPF (142). 
Still, substantial amount of research has been done to elucidate mechanisms to either 
explain or reject role for immune system to no avail.  
There are autoimmune diseases that have an established connection with developing 
pulmonary fibrosis such as systemic sclerosis (158), Sjögren's syndrome (159) and 
rheumatoid arthritis (160) Though if an underlying cause can be found the fibrosis by 
definition is no longer idiopathic. However, autoimmunity in IPF has been implicated in 
previous research (142), demonstrating reactivity to various potential targets such as 
vimentin (161-163). Although these autoimmune reactions have not been fully understood 
or comprehended, this provides an interesting approach to illuminate pathogenic 
mechanisms (164, 165). So far only small studies have been conducted, to improve chances 
of finding answers there is a need for a larger study looking at vastly greater numbers of 
potential autoimmune targets.  
  
 
  27 
6 SARCOIDOSIS AND IPF 
Both in Sarcoidosis and in IPF there are clinical subgroups that present with higher rate of 
fibrosis (sarcoidosis) and a more rapid disease progression rate (IPF) (14, 166). Moreover, it 
is currently impossible, within the respective disease, to distinguish the patients with worse 
prognosis from those with a better prognosis on an early stage. IPF and sarcoidosis share 
other aspects as well, humoral anomalies are frequent in both sarcoidosis and IPF (167), 
there are even cases of concurrent sarcoidosis and IPF (168). Specific autoantibodies or 
antigens could potentially influence disease outcome or at least serve as a marker of disease 
development (14, 167). Potential biomarkers would help physicians diagnosing the disease 
in an earlier state as well as provide drug targets in aid of treating patients (3, 4).  
 
7 PROTEOMICS  
Proteomics is the science and study of function of proteins and peptides, the phrase was 
coined more than 20 years ago (169), played off by the term proteome formulated a few 
years prior (170). In this paper, proteomics will only refer to proteins and peptides in the 
human system, though proteomics in general encompass proteins of all organisms. 
Proteomics is more dynamic in nature compared to s (genomics), where genes in a cell are 
close to invariable the proteome will alter over time and between cells. Genomics 
encompass the information of what potentially can occur, while proteomics describe what is 
happening at the present moment. 
Due to posttranslational modifications (PTMs) the variability of proteins increases even 
further (171). The PTMs refer to the process of adding a functional group by covalent 
binding to the modified protein. The modifications are usually carried out by various 
enzymes in order to enhance or modify the function of the protein. The most common PTM 
is phosphorylation where a phosphate group is attached to the protein, which is a typical 
way of regulating enzyme activity (172). Another feature among proteins is to attach 
carbohydrate molecules, a procedure known as glycosylation, which can promote of affect 
protein folding as well as structural stability (173, 174). In project III we investigated if the 
glycosylation variations to the sugar moieties of the Fc region of antibodies could be related 
to inflammation in lung diseases. 
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This high variability of proteomic expression both inter- and intra-individually yield certain 
challenges in analyzing proteins, such as reproducibility, and accounting for protein 
degrading (175, 176). Previously the quantification and detection of proteins were done 
through RNA analyzing methods; however these were shown to be inaccurate in protein 
content due to inconsistent transcription of mRNA (177-179).  
The ways of analyzing proteins has increased, and keeps expanding, though essentially 
proteomic can be divided into top-down or bottom-up approaches (180, 181). Top-down 
analyzes entire proteins or substantial fragments of proteins; this approach is beneficial for 
analyzing PTMs or isoform determination (182). Bottom-down analyzes small peptides or 
metabolites of proteins, which has methodological benefits over the top-down approach 
when it comes to protein fractionation and ionization (182). Both strategies have their 
advantages and disadvantages, the reason for choosing either depends on the research 
question. The bottom-down approach can be further categorized into targeted or non-
targeted analysis. Targeted means the investigation of a known metabolite, this method is 
used for validation of hypotheses and thus is hypothesis driven. Whereas for non-targeted 
(also known as shotgun approach) the metabolites are unknown and the analysis is 
unbiased, this approach is better used for discovery rather than validation (183, 184). In 
project III we used LC-MS/MS which is a non-targeted bottom-down approach, compared to 
the immunoassay of bead array analysis which is closer to a targeted analysis method.   
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8 MATERIALS AND METHODS 
This section provides an overview of certain methods and set-ups used in this thesis, as well 
as some additional considerations. Please review the original articles for a more detailed 
description of the methodologies.  
8.1 ETHICAL APPROVAL AND CONSIDERATIONS 
The collection and use of patients samples and information been approved by the 
Stockholm regional ethics committee. The ethical permissions for are project I-III; main 
application no. 2005/1031-31, complementary applications 2009/20-32, 2011/35-32, 
2012/132-329. In addition to the previous applications, project IV requires the 
complementary application 2021/00802 to be able to analyze and handle patient 
information of IPF samples from international collaborators. The collaborators themselves 
have ethical approval from local ethic committees (Netherlands - BIOBANK DATA ILD R-
05.08A, France - CPP Ile de France I: no 0911932). 
Patients are admitted to the hospital and undergo a diagnostic investigation, with regard 
to interstitial pulmonary diseases, this usually means they perform a bronchoalveolar 
lavage (BAL) and biopsies, from which the material collected can be used for both clinical 
investigation as well as research. However, if a secondary lavage is performed for research 
interests only, this will be on a volunteer basis and compensated as such.  
Volunteers are healthy individuals who participate in the studies of free will and not to 
diagnose a disease. They receive, however, monetary compensation.  
Another point to consider is the samples collected contain a lot of biological information 
(DNA information etc.) which usually is investigated together with clinical information 




8.2 STUDY SUBJECTS 
In the clinic, we routinely screen patients to be eligible for research and after an informed 
consent is obtained, samples (both blood and BAL fluid) are collected and stored in our 
biobank.  All of the papers rely on the existence of sample material from patients and 
healthy controls. 
Paper I - The same cohorts as in project II was used in the discovery phase for project I. In 
the verification phase, an additional 216 sarcoidosis BAL samples were added together with 
33 samples from healthy controls.  In total, 251 BAL samples from sarcoidosis patients and 
49 BAL samples from healthy controls were included in this project.  All sarcoidosis patients 
had an active disease, defined as either progression on chest radiograph, physical symptoms 
or worsened lung function in accordance with a sarcoidosis disease. All patients and healthy 
controls gave written and informed consent.  
Paper II - This paper included 345 BAL and 141 serum samples from LS, nLS, asthma and 
healthy controls in the screening stage. An additional 22 BAL samples from fibrosis patients 
and 269 serum samples from patients with myositis were added in a subsequent verification 
stage. The same criteria for active disease as in paper I for sarcoidosis patients were applied. 
The sarcoidosis patients were diagnosed according to the American Thoracic Society 
(ATS)/European Respiratory Society (ERS)/ World Association of Sarcoidosis and Other 
Granulomatous Disorders (WASOG) criteria (109) and subgrouped into LS and nLS cohorts. 
Healthy controls were neversmokers and did not take any prescription drugs. The asthma 
patients were mild allergic asthma patients, currently out of season and with access to 
bronchodilators but not under corticosteroid treatment. All patients and healthy controls 
gave written and informed consent. 
Paper III - BAL and serum samples from both LS (n=12) and nLS (n=12) were initially 
analyzed using LC-MS/MS after melongel purification. As controls, a cohort of severe 
asthmatics (n=20) and a cohort of RA-patients (n=14) were added together with healthy 
subjects (n=12). The severe asthmatic patients stood on a regime of continuous high dose 
corticosteroid inhalations. Clinical characteristics and biomarkers measured as part of the 
BIOAIR study included BMI, sputum and blood cell counts, exhaled NO, lung function, serum 
periostin, YKL-40, total IgE and CRP.  For the RA patients the Fc-glycan information were 
taken from published data using the mean values between anti-citrullinated peptide 
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antibodies (ACPAs) and the remaining paired polyclonal IgGs from respective patient. For 
more details see Lundstrom et al (185). 
Paper IV - Through international collaborations in France and Netherlands, two sets of IPF 
cohorts were provided. In total a 154 serum samples (France) and 99 matched serum and 
BAL samples (Netherlands) were provided. These samples were shipped on dry ice and then 
treated exactly the same as the rest of the samples from the other cohorts. The original 
cohorts from paper I and II functioned as controls.  
8.3 BRONCHOALVEOLAR LAVAGE AND PROCESSING OF SAMPLES 
Bronchoscopy is a crucial procedure for medical doctors to assess a patient's airway, and 
essential for the ability to take samples from the mucosa or pulmonary tissue.  
 
 
Figure 7. Bronchoscopic procedure and collection of BAL. A) Via inserting a flexible bronchoscope into the 
patients' airways, the physician can observe the epithelium and take samples, such as BAL. B) Sterile saline 







For bronchoalveolar lavage a flexible bronchoscope is inserted into the airways via one of 
the nostrils, then 50 ml of saline (0.9%) solution is instilled in the middle lobe, this 
instillation process is repeated 5 times for a total of 250ml of saline solution, though not all 
fluid is recovered. The samples are then without delay put on ice and transported to the 
laboratory, then processed, aliquoted and stored in -80 or -150 until further use. BAL cell 
count is performed by separating the cells from the supernatant, then fixating the cells on 
cytospin slides with cells subsequently stained before determining the differential count by 
microscope. For all projects the samples were processed in the same way, with minimal 
freeze thaw cycles. At processing, the samples were thawed in cold water and then 
centrifugated at 4000/g using ultrafiltration tubes (Amicon Ultra-4, 3kDa, Cork, Ireland) 
8.4 MULTIPLEX BEAD ARRAY 
The method primarily used in this thesis is an immunoassay based on multiplex array 
techniques; these techniques emerged in the beginning of the 2000s, initially only being 
able to analyze a few samples at a time (186, 187). Since then the capacity has greatly 
increased and it is now theoretically possible to run the entire proteome (188).  
The major benefit of these microarray technologies is the opportunity to screen large ranges 
of antigens on planar arrays, using an unbiased selection of antigens, in combination of 
extended analysis with the bead-based assays. 
In our work we used multiplex bead array analyses in project I, II and IV, in which color-
coded beads are coupled with either antigens or antibodies and then incubated with 
biotinylated patient samples. The samples can be analyzed by a reader to generate semi-
quantitative results for statistical analysis (189). A schematic overview of the procedure can 
be viewed below (Figure 8). In this set-up antibodies are coupled with the beads in order to 
detect antigens in patient samples (as done in paper II) (190), the method can be turned 
around and the beads can be coupled to proteins in order to detect autoantibodies in the 
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Figure 8. Schematic of the mSBA method. Autoantibody detection: A) Patient samples are aliquoted into 
plates; simultaneously selected antigens are coupled to microscopic color coded magnetic beads with an 
identifiable ID; bead-coupled antigens are pooled; the pooled antigen stock is added to each sample on the 
plate separately; a phycoerythine labeled anti-IgG is added to each well on the plate; following incubation each 
sample is fed through a reader detecting the simultaneous presence of bead/antigen connected to sample 
antibody and the anti-IgG antibody. Thus, each patient is tested for presence of the autoantibodies of interest. 
Protein detection: B) Each patient sample is aliquoted to a well; all patient samples undergo biotinylation; 
simultaneously; antibodies (ab) towards proteins of interest are aliquoted to individual wells and coupled to 
magnetic beads with an identifiable ID; aliquoted ab are pooled; together with streptavidin, patient samples 
are incubated individually with pooled ab; each sample is run separately. Detection similar to (A), subsequently, 
each patient sample is tested for presence of the proteins of interest. STR.VIDIN - Streptavidin 
 
8.5 PULMONARY SPIROMETRY  
Patients in all papers go through lung function tests, spirometry, to assess their pulmonary 
status. Certain parts of a spirometry are more relevant to certain patient groups. For 
example forced expiratory volume under 1 second (FEV1) is more relevant to asthmatic 
patients since it measures obstructivity in the small airways, whereas the diffusing capacity 
for carbon monoxide (DLco) is more relevant to IPF patients, since excess pulmonary fibrosis 





In mass spectrometry the protein/peptide samples are analyzed through the ratio between 
mass and charge. This method can be used both for wide detection of many proteins as well 
as analysis of specific protein targets. In project III, liquid chromatography tandem mass 
spectrometry (LC-MS/MS) was applied in a shot-gun approach in order to characterize the 
Fc-glycan part of the IgG in serum and BAL fluid of sarcoidosis patients and healthy 
controls(182). 
8.7 ELISA 
Enzyme-linked Immuno-sorbent Assay (ELISA) belongs to the category of immunoassays, 
similar to the bead array method. In contrast to mSBA, ELISA is not a high throughput 
method, however, several commercial kit towards virtually all proteins are readily available. 
In Project I we utilize a sandwich ELISA-kit, as per manufacturers protocol (DY279, R&D), to 
detect presence of autoantibodies towards CCL2 and for validation of previous results from 
the mSBA method. 
8.8 STATISTICAL ANALYSES 
For all papers, univariate analyses were performed using Student’s t-test, with equal or 
unequal variance conditioned by F-test. 
P-values were corrected using FDR concordant with total number of comparisons. Linear 
regression analysis was performed for the correlation between BAL and serum. Correlation 
between variables and clinical factors were obtained using two-tailed Pearson or Spearman 
correlation (depending on normality test). Statistical software from Graph Pad Prism (Graph 
Pad Prism, GraphPad Software Inc., LaJolla, USA) was used to do analyses for paper I-IV.  In 
paper III, Multivariate modelling using Principal Component Analysis (PCA) and Orthogonal 
projections to latent structures discrimination analysis (OPLS-DA) was done using SIMCA 
14.0 with mean centring, UV scaling, and log transformation. Performance of the model was 
described through cumulative correlation coefficients (R2), and the predictive ability (Q2) 
through seven-fold cross validation calculations and p[CV-ANOVA]). In paper III the data was 
normalized by GlcoAge index. 
 
 
  35 
For paper I and IV, in order to compare the sample groups, the readout intensities from the 
planar and bead-array analyses were converted into binary variable based on reactivity 
frequencies for each sample, i.e. the sample was determined to be reactive or non-reactive. 
Correction for multiple testing was applied through false discovery rate (FDR) in accordance 
with the Benjamini-Hochberg method (also in paper III). In paper I and II, receiver operating 
characteristic (ROC) was used to discern sarcoidosis patients from healthy individuals by 
relative antibody intensities. 
Different methods were applied for paper II and paper IV when it came to determine 
reactivity, and the use of reactivity cut-offs. Paper II was initiated by screening from planar 
arrays, and a sample median was determined for each batch. After which a high cut-off 
value was set to sample median + 20x median absolute deviation (MAD) and a low threshold 
of sample median + 10x MAD. Antigens were selected for further analysis if two or more 
sample met the high threshold and/or if four or more samples met the low threshold. In 
paper IV an antigen specific cutoff was assigned using the distribution of resulting 
reactivities across a selection of possible MAD cutoffs by determining where the slope is 
nearing a local minimum beside the highest peak (i.e. where the curve flattens out after the 
highest point). Figure 9 illustrates both methods; the implications of the two strategies are 
discussed in greater detail in "Result and discussion" section of paper IV. 
 
Figure 9. Overview of the methods to determine reactivity. A) From paper II, after screening two thresholds 
were determined. The higher threshold was set to sample median + 20xMAD and a lower threshold of sample 
median + 10xMAD. For an antigen to be reactive, either two samples had to meet the higher criteria, or four 
samples had to meet the lower criteria. B) An antigen specific cutoff was assigned using the distribution of 
resulting reactivities across a selection of possible MAD cutoffs by determining where the slope is nearing a 
local minimum beside the highest peak (Representative example). MAD- median absolute deviation.  
 
36 
9 RESEARCH AIMS 
In this thesis we were investigated the role of autoantigens, autoimmune antibodies and 
immunopeptides in two interstitial diseases, sarcoidosis and idiopathic pulmonary fibrosis 
(IPF). The diseases do not have a completely known pathophysiology or aetiology. We 
hypothesize that identification of specific antigens can help elucidate of the pathogenesis of 
sarcoidosis as well as of IPF, and in the long perspective this could lead to therapeutic 
targets.  
The aims are therefore to: 
- Identify key markers of inflammatory responses in sarcoidosis and IPF  
- Identify new immune targets (cells, cytokines) for possible treatment. 
- Identify peptides (externally derived or auto-antigens) implicated in sarcoidosis 
or IPF. 
- Generate targets for functional test/antigens capable of stimulating T-cells 
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10 RESULTS AND DISCUSSION 
10.1 PROJECT I  
Sarcoidosis Patients Display Elevated Levels of FN1 and CCL2 in BAL Fluid 
In this project we set out to investigate the protein profile of sarcoidosis patients in order to 
find proteomic targets associated with disease and/or inflammation.  
We used the mSBA platform in BAL samples to analyze antibodies targeting selected 
proteins from the literature. In addition to the two sarcoidosis groups (LS and nLS), BAL fluid 
from asthmatics and healthy individuals were included for extended reference. 
Initial protein concentration analyses showed a significantly higher concentration for the 
processed BAL samples of sarcoidosis patients compared to both healthy controls and 
asthma patients (p<0.0001). In addition, there was also a prominent diversity in 
concentration throughout all samples ranging from 0.2 to 9.8 mg/ml. 
Following analysis of 68+ 249 BAL samples from sarcoidosis, asthma and healthy controls by 
multiplex bead array,  fibronectin 1 and C-C motif chemokine 2 (CCL2) were the two 
proteins with the highest significance. These proteins had significant elevated presence in 
the sarcoidosis cohort compared with controls (p<0.001).  
In order to verify the results for FN1 and CCL2 from the first assay, the protein levels were 
explored using the original bead array with an additional independent antibody, together 
with a sandwich immunoassay on the bead array. The results from the three assays 






Figure 10. FN1 and CLL2 levels in BAL. A) Elevated concentration of FN1 and CCL2 were discovered in BAL from 
sarcoidosis patients compared to controls. B) Sandwich immunoassay showing verified results from figure (A) 
Outliers were omitted from the figure for illustration purpose, significant differences between groups indicated 
(p < 0.05).  Adapted from (191) 
 
While the quantity of FN1 and CCL2 in BAL fluid was elevated in sarcoidosis patients in 
contrast to controls and asthma patients, the measured protein levels were unable to 
separate the LS subgroup against the nLS subgroup. Unlike the BAL samples, analysis of 
serum samples yielded no statistical significant difference between the cohorts with regard 
to protein levels. 
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Figure 11.  ROC analysis of FN1 and CCL2. In order to establish if the levels of FN1 and CCL2 would separate 
sarcoidosis from controls, ROC analysis was carried out. Results indicated area under the curve (AUC) of 0.91 
for FN1 and 0.71 for CCL2. (190). 
 
In order to evaluate if the levels of FN1 and CCL2 would separate patients with sarcoidosis 
from healthy controls, a ROC analysis was executed. Results showed an area under the 
curve (AUC) of 0.91 for FN1 and 0.71 for CCL2 (Figure 11). 
In addition to the proteins found to differ between sarcoidosis and controls, the protein 
cadherin (CDH5) correlated with BAL findings. The CDH5 protein had a positive correlation 






Discussion of project I 
Here we set out to investigate the prevalence of proteins in serum and BAL from sarcoidosis 
patients in order to find sarcoidosis associated proteins. Even though sarcoidosis is viewed 
as systemic disease, over 90% of patients have manifestations in the lung; therefore, using 
BAL is likely the most suitable approach for identifying proteins in this condition. Several 
proteins were also discovered with elevated levels in BAL of sarcoidosis patients compared 
to controls. Though these differences were not represented in serum samples, indicating 
that even though sarcoidosis is a systemic disease, the lung is the primary site for the active 
disease. 
Two proteins (FN1 and CCL2) stood out with the most significant differences between BAL 
and controls. Elevated levels of fibronectin have previously been demonstrated in BAL fluid 
from interstitial lung diseases including sarcoidosis (192-195). The previous studies used 
ELISA, and the overlapping results between these studies and our data suggest that the 
bead array assay is appropriate for analyses in BAL. Moreover, the similar levels of FN1 in 
serum between sarcoidosis patients and controls corresponds to earlier findings in plasma 
(194). The current opinion considers increased levels of fibronectin in BAL as an indicator for 
inflammation in the lung, more so than a disease specific response of sarcoidosis patients 
(192, 196, 197).  
We discovered elevated levels of CLL2 in BAL of sarcoidosis patients compare to controls, 
these findings are concordant with previous studies where CCL2 as well as CCL5 was  in BAL 
in all sarcoidosis stages (198).  
We were unable to detect differences in serum levels of CCL2 between cohorts, this finding 
is consistent with earlier papers (199). Neither could the prevalence of any protein in the 
study distinguish the LS and nLS subgroups. This is fairly unexpected since LS and nLS have 
distinct clinical phenotypes and genetic variation (2). Nevertheless, this project presents 
possible protein targets for further investigations in pulmonary disease.  
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10.2 PROJECT II 
Profiling of the Autoantibody Repertoire in Sarcoidosis 
In this project we set out to characterize and relate the antibody repertoire between 
sarcoidosis patients and healthy controls. 
Results from the planar arrays demonstrated a high heterogeneity between individuals 
when it came to antigen reactivity, where some samples were only reactive towards a few 
antigens and others demonstrated reactivity to several. Even after converting the sample 
intensities into binary variable by applying cut-off criteria (see method section), i.e. each 
sample was determined to be reactive or non-reactive for each antigen, a major individual 
variation persisted, although a majority of the reactivities were confined to single individuals 
(Figure 12A).  A noticeable variation between individuals was detected when compiling the 
total sum of reactivities, ranging between 0 to 200 antigens per sample. A trend was 
observed where the sarcoidosis patients displayed a higher total reactivity frequency 
compared to controls. This was particularly evident for the nLS group vs controls, where a 
significant difference could be observed (p=0.05) (Figure 12B). 
 
Figure 12.  Screening and antigen selection from planar arrays. (A) Reactivity profiles for all samples groups 
revealed a major individual variation, although a majority of the reactivities were confined to single individuals. 
(B) A plot displaying total number of reactive antigens per group. Sarcoidosis patients demonstrate a higher 
total reactivity frequency compared to controls, particularly non-Löfgren patients, which compared to controls 
had a significantly higher total reactivity frequency. (P < 0.05). Adapted with permission of the American 
Thoracic Society. Copyright © 2021 American Thoracic Society. All rights reserved.(189) 
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By calculating and comparing reactivity frequencies between cohorts, a set of four antigens 
were of specific interest. The set consisted of Zinc finger 688 (ZNF688), Mitochondrial 
ribosomal protein L43 (MRPL43), Nuclear receptor coactivator 2 (NCOA), Adenosine 
diphosphate–ribosylation factor GTPase activating protein 1 (ARFGAP1).   
ZNF688 and MRLP43 displayed the highest difference between sarcoidosis patients and 
healthy controls. ZNF688 demonstrated reactivity in 71% of the sarcoidosis patients, 45% in 
healthy controls and 53% in patients with asthma. The ZNF 688 antigen was also the target 
with the highest total reactivity throughout all samples with 56% reactivity frequency. For 
MRLP43 the reactivity in sarcoidosis patients were 12% compared with 2% in the healthy 
controls and no reactivity in the asthma cohort. A difference could be observed when 
comparing LS and nLS where 14% of LS patients demonstrated reactivity towards MRLP43 
while only 2% of the nLS did (Figure 13).   
 
 
Figure 13. Summary of reactivity frequencies.  Zinc finger protein 688 (ZNF 688), Adenosine diphosphate–
ribosylation factor GTPase activating protein 1 (ARFGAP1), Nuclear receptor coactivator 2 (NCOA2), 
Mitochondrial ribosomal protein L43 (MRLP43), Löfgren syndrome (LS). non-Löfgren syndrome (Non-LS). 
Adapted with permission of the American Thoracic Society. Copyright © 2021 American Thoracic Society. All 
rights reserved. 
Conversely, a stronger difference between reactivity frequency of LS and nLS was observed 
for the protein fragment of NCOA2. For NCOA2 only 2% of the LS patients displayed 
reactivity compared to 11% in nLS patients. In addition to the other findings, ARFGAP1 also 
displayed high reactivity throughout all cohorts. 
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Receiver operating characteristic (ROC) was performed for reactive samples from ZNF688 
and ARFGAP, where ARFGAP was the antigen with high reactivity across all cohorts. Area 
under the curve (AUC) analysis showed values of 0.79 for ZNF688 and 0.76 for ARFGAP1 
signifying that ARFGAP, despite similar reactivity between cohorts, could distinguish 
patients from healthy controls comparable to ZNF688 based on the relative intensity levels 
(Figure 14). In addition, both antigens showed significant difference in a two-group 
comparison between controls and sarcoidosis patients where both displayed a significant p-
value of < 0.01.  
 
Figure 14 .Sample classifications. (A) ROC analysis using only reactive samples demonstrating relative intensity 
levels of antibodies toward zinc finger protein688 (ZNF688) and adenosine diphosphate–ribosylation factor 
GTPase activating protein 1 (ARFGAP1). (B) Levels of reactive antibodies towards ZNF 688 and ARFGAP1 in 
samples from patients with sarcoidosis compared to healthy controls. Both antigens with P < 0.001. Area under 
the curve (AUC), Median fluorescent intensity (MFI). Adapted with permission of the American Thoracic 





Discussion of project II 
Despite that the pathophysiology suggest a cellular mediated immune response through 
CD4+ helper cells, there are indications of autoimmunity, or autoimmune components in 
sarcoidosis. One is the proposal of Vimentin as an autoimmune target (200), to add to the 
discovery of the four targets in our paper. Another is the concurrence of sarcoidosis with 
other autoimmune disorders (201), where there is one autoimmune disease there can be 
more (202). Another, slightly contradicting, but interesting fact is that most if not all people 
demonstrate the ability to produce autoantibodies, however, far from all subjects have a 
disease. It highlights the importance to separate autoimmunity with the presence of 
autoantibodies; presence is not equal to function.   
When comparing the antibody reactivity profiles in our study there was a considerable 
variability, most of the antigens only exhibited reactivity in single individuals. This is 
coherent with previous findings which has stated strong individual variation patterns (12, 
21).  
In this type of hypothesis generating set-ups with a high throughput system there is a higher 
likelihood of discovering differences between cohorts, than compared to a hypothesis 
driven one. When performing multiple testing, statistically, you increase the chance of 
finding significant differences. However, the differences might a product of repeated testing 
and thus not accurate. Hence it is important to correct for the increased probability of 
finding significant differences. The trade off is that true differences could be masked if a too 
harsh method is applied; in our investigation of these antigens the results were not 
statistically significant after correcting the P-values for multiple comparisons using false 
discovery rate (FDR). 
The sarcoidosis group, and nLS cohort in particular, demonstrated a higher total number of 
reactivities compared to controls and asthma patients, potentially reflecting a more 
prominent inflammatory state, though this group has previously been described with 
hypergammagloublinemia (203).  Furthermore, increased levels of IgG and IgM secreting 
cells in BAL has been observed in sarcoidosis patients compared to healthy controls, 
however there was no difference in serum (203). Patients with asthma were more similar to 
healthy controls, with regard to total number of reactivities, than to sarcoidosis patients. It 
is important to note that these patients were mild allergic asthmatics out of pollen season; 
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therefore it is likely that the asthmatics were in a "steady state". It also important to note 
that, in this paper, the reactivity definition is based on a cut-off values that can be varied 
and thus yield altered frequency levels and outcomes. The method in this paper differs from 
that of project IV which uses a statistical model to determine the cut-off levels for each 
sample.  
This paper set out to profile the autoimmune repertoire in patients with sarcoidosis with 
regard to both BAL and serum. The paper indentified four potential autoimmune targets 
that were present in both BAL and serum. Particularly ZNF688 and ARFGAP1 demonstrated 








10.3 PROJECT III 
Altered Fc Galactosylation in IgG4 in Serum for Chronic Lung Diseases 
We explored the possibility of Fc glycans from BAL and serum to associate with pulmonary 
inflammation, as well as the correlation of glycosylation status between BAL and serum. 
Multivariate analyses were carried out in order to explore the general trend, as well as the 
correlation within each individual, between serum and BAL profiles. A principal component 
analysis (PCA) demonstrated a separation (R2=0.46, Q2=0.35), where the two main 
proponents behind the separation could be attributed to differences in BAL versus serum in 
addition to individual-specific differences when it came to cohort with or without the 
combination of age.  
For further study of which Fc glycans were propelling the separation between BAL and 
serum, an orthogonal projection to latent structures- discrimination analysis (OPLS-DA) was 
performed. The OPLS-DA analysis included all sample groups, and the successfully separated 
BAL from serum with a robust model (R2=0.90, Q2=0.85, p=1.33×10−26 by cross-validated 
(CV)-ANOVA)). In the glycan screening, 31 Fc glycans variants out of a 64 total correlated 
with 95% confidence in serum while only 5 variants correlated with the same confidence in 
serum. This would suggest a more variable IgG composition in serum compared to BAL with 
regard to Fc glycan expression.  
When investigating Fc glycan differences between patient subgroups and controls, OPLS-DA 
analysis was able to discern between healthy controls, LS and nLS (R2=0.28, Q2=0.24, 
p=4.4×10−12). In this analysis, controls and LS patients had the biggest difference, while nLS 
was positioned in between (Results shown as: mean±SD tcv[1]; Controls=2.9±2.4, 
LS=−0.9±2.1 and nLS=−2.1±2.1). Here nLS seems to distance itself further from healthy 
controls than LS, interestingly since LS is usually viewed as the more active disease 
compared to nLS which is of a more chronic character.  
We used the major agalactosylated form (more proinflammatory, FA2) and the major 
galactosylated (less proinflammatory, FA2G2), to investigate the correlation between serum 
and BAL for the ratio of log(FA2/FA2G2) for each sample (Figure 15).  The log(FA2/FA2G2) 
ratio correlated particularly well for IgG4 in all groups (R2all=0.95), while the other IgG 
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Figure 15. Intra-individual correlations between BAL and serum. Graphs showing the correlation between BAL 
and serum using the logarithmic ratio of the agalactosylated form (FA2) and the galactosylated form (FA2G2) 




=0.87) and c) IgG2/(3) (R
2
=0.76). H - Healthy controls; nLS  - non-
Löfgren’s syndrome; LS - Löfgren's syndrome. #: Dual data-points for individual who underwent bronchoscopy 
twice with a year in between BAL samplings. 
 
The levels of truncated or agalactosylated Fc glycans increases with age, additionally, the 
increase is also not linear. So in order to examine how much the difference in 
galactosylation is due to disease and not age, and to correct for the age difference between 
cohorts, we normalized our data with the help of GlycoAge index (204). After GlycoAge 
index normalization, log(FA2/FA2G2) of IgG4 stayed significant both in BAL (p=1.1×10
−2) and 
serum(p=1.6×10−2). 
To examine whether log(FA2/FA2G2) of IgG4 is disease specific to sarcoidosis or not, we 
added serum samples from severe asthmatic (SA) patients and previously published Fc 
glycan data from RA patients to the analyses. The results from comparisons to the 
aforementioned groups (LS and nLS) evidently demonstrated that increased age-corrected 
IgG4 log(FA2/FA2G2) ratio is not specific to sarcoidosis.  The analyses showed that most of 
the SA patients had very high log(FA2/FA2G2) IgG4 ratios in serum (0.73±32). The RA group 
scored lower log(FA2/FA2G2) ratio (0.37±26) than sarcoidosis and asthma patients, but still 
slightly higher than healthy controls.  
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A significant difference in log (FA2/FA2G2) ratio in serum was observed between healthy 
with RA patients and the three cohorts with pulmonary inflammatory disorders (LS, nLS and 
SA) (p=9.2x10-4) (Figure 16). Based off these results we propose that age-corrected 
log(FA2/FA2G2) ratio in serum can be separated in low, medium and high-range values 
(⩽0.3, 0.3–0.6, ⩾0.6), where  the high-ranged values suggest strong inflammatory activity in 
the lung. (Figure 16a and 16b). 
In addition, using ROC analysis, the GlycoAge corrected log(FA2/FA2G2) ratio of IgG4 in 
serum could separate sarcoidosis and severe asthmatics (SA) vs. healthy and RA subjects 
with a mean ± standard error (SE) AUC of 78±6%.  When clustering the more chronic lung 
disorders (nLS and SA) and comparing them to healthy and RA, the AUC increased to 83±6%. 
Furthermore, when only comparing against healthy controls the AUC increased to 90±5% for 
the nLS + SA group (Figure 16). 
 
Figure 16. Ratios for log(FA2/FA2G2) across all groups. a) Age-corrected serum log(FA2/FA2G2) ratio of IgG4 
for healthy controls (H),  rheumatoid arthritis (RA), Löfgren’s syndrome (LS), non-LS(nLS) sarcoidosis and severe 
asthma (SA). Dotted lines indicate thresholds for low- (⩽0.3), medium- (0.3–0.6) and high-range values (⩾0.6). 
b) The disposition (%) for each sample group according to the low-, medium-, high-value ranges. c) AUC values 
from ROC analyses demonstrating comparisons between sample groups with and without pulmonary diseases. 
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Discussion of project III 
At times it can be challenging to differ between sarcoidosis and IPF, as stated previously, 
there are even cases of concurrent disease (168). Furthermore, neither sarcoidosis nor IPF 
have any good markers for prognosis that is universal for all patients. For sarcoidosis 
patients there is a connection to better prognosis if you express the DRB1*03 haplotype, or 
if you have high levels of AV2.3+ T-cells in BAL, though this is not applicable for everyone. 
Usually, invasive investigations are needed to be performed in order to acquire samples for 
analysis, though particularly bronchoscopy is generally viewed as an uncomfortable 
procedure by patients. A marker of inflammatory status that can be captured via a blood 
test would be of great benefit in clinical practice. By using the information of glycosylation 
status of different IgG subsets from our study, it would be possible to acquire information of 
inflammatory status in the lung from a standard blood sample.  
In this paper we demonstrated that Fc galactosylation status of IgG in BAL and serum 
correlates closely, and remains significant even after correcting for age differences. The 
correlation was particularly strong for IgG4 in patients with pulmonary disorders compared 
to controls and RA patients. Alterations in IgG Fc glycan domains has been reported in 
several studies, most notably regarding RA patients where the IgG1 Fc glycans are more 
prominent but less galactosylated (35, 185, 205).  
In this paper we successfully indentified IgG4 galactosylation status as a candidate marker 
for chronic respiratory inflammation. This marker also demonstrate a high correlation 
between BAL and serum (R2=0.95) and could be readily available through blood sampling. As 
it was designed as a pilot study the study cohort was drastically skewed when it came to age 
and sex differences between cohorts, though the sex matched RA patients exhibited no 
difference in galactosylation between men or women. With regard to age differences the 
study results were adjusted accordingly. Overall the project presents an interesting pathway 
for future biomarker investigations in Sarcoidosis.  
Based on the results of project III we conclude that the Fc galactosylation status of IgG4 




10.4 PROJECT IV   
High Throughput Screening and Comparison of IPF and Sarcoidosis Samples 
The mSBA approach is used for both sarcoidosis and IPF samples in order to evaluate 
similarities and differences between fibrosis associated diseases. 
When observing the reactivities across the entire set of samples, Zinc finger 688 (ZNF688), 
Collagen 5A1 (COL5A1), displayed the highest reactivity frequencies in BAL (84.7% and 
73.3% respectively) and blood (26.2% and 15.1% respectively)  Both heat shock protein A4 
(HSPA4) (BAL 13.1% and serum 33.2%) and ADP-ribosylation factor GDPase-activating 
protein 1 (ARFGAP1) (BAL 15.0% Serum 40.7%) demonstrated high reactivity frequencies in 
both BAL and serum, though not as distinct as COL5A1 and ZNF 688 (Figure 17).  
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Figure 17. Overall reactivity frequency. Initial screening. Reactivity frequency (Percentage of reactive 
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When evaluating IPF and sarcoidosis patients, the COL5A1 target showed a statistically 
significant higher frequency of reactivity between both IPF and nLS compared to LS in BAL 
(p<0.005 and p<0.05 respectively, (Fig 18a).There were high reactivity in BAL for ZNF688, 
ARFGAP and HSPA4 for both LS and nLS, though no statistical difference could be 
distinguished between the groups (Fig 18b). For IPF the difference was also significant in 
serum (p=0.007), however, no difference could be observed in serum between LS and nLS 
(p=0.49). Also, no statistical difference could be discerned comparing IPF to nLS patients 
(p=0.3) in either BAL or serum (Figure 18).   
 
Figure 18. Reactivity frequency against COL5A1 in BAL and Serum. Comparison of the different cohorts. Line 
with** indicates significant difference between groups at p<0.005, a * indicates significant difference between 
groups at p<0.05 
In addition to the IgG reactivity assays, an epitope mapping analysis of the COL5A1 protein 
fragment (Table 1 supplementary) was performed by means of peptide array. Results 
displayed clear heterogeneity in the reactivity between the compared groups, though 
peptide number 8 (Y Y T E G D G E G E T Y Y Y E) & 10 (G E G E T Y Y Y E Y P Y Y E D) 
(Supplementary Table 2) yielded high signals across all diseases, as well as healthy controls, 
in both serum and BAL (Fig 19 A-F). Despite only performed in serum, (Figure 19 A) results 
seem to indicate a preference of reactivity towards peptide number 1-3 in the French IPF 
cohort. For the matched BAL and serum samples of the Dutch cohort a clear overlap of 
preferred reactive peptides can be seen in Figure 19 B. The same can be observed for the 
unmatched cohorts of LS and nLS as seen in Figure 19 C and D.  
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Figure 19A-F. COL5A1 epitope mapping analysis in Serum and BAL. Each graph represents a cohort with its 
corresponding MFI value (y-axis) for Serum (Left) and BAL (right) for each peptide (1-13) (x-axis). Figure F 
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Discussion of project IV 
In this study we investigated potential autoreactivity in serum and BAL samples from IPF and 
sarcoidosis patients by high-throughput microarray analyses. One of our main findings was 
that nLS sarcoidosis showed similarities to IPF regarding prevalence of autoantibodies in 
general and COL5A1 in particular. In fact, nLS were more similar to the IPF cohorts than to 
LS. This is interesting considering the tendency to develop fibrosis in both IPF and nLS, but 
not in LS nor the asthma or healthy controls. For the protein fragment of collagen 5A1 
(COL5A1), a high reactivity frequency was found in both IPF and nLS but not in LS, further 
emphasizing the similarities between the two cohorts able to develop fibrosis. 
When it comes to determining whether a sample is reactive or not, a different method was 
applied in this project compared to project II. In this project we assigned an antigen specific 
cutoff using the distribution of resulting reactivities across a selection of possible MAD 
cutoffs by determining where the slope is nearing a local minimum beside the highest peak 
(i.e. background peak)(Fig. 9). The advantage to use this method compared to setting 
subjective thresholds is that this method is unbiased, therefore you run less risk of 
inadvertently setting threshold that benefit your result, it is also adjusted for each individual 
antigen. The downside is that some antigens display a slow decline in reactivity distribution, 
which makes the initial background peak drawn out. This leads to very high cutoffs which 
run the risk of cutoffs being too strict and loose valid data point. Nonetheless, the method 
used in project IV appears to be more robust and works reasonably well. 
IPF and nLS displayed higher levels and frequencies of auto-reactivity compared to all other 
diseases and controls, both in BAL and in serum. Of specific interest are the protein 
fragments representing ZNF688 and COL5A1 with significantly higher reactivity frequencies. 
Anti-ZNF688 reactivity has been implicated in both SLE and sarcoidosis, as noted by 
previously published papers (189, 206). Furthermore, in lung tissue it is expressed solely by 
ciliated epithelial cells that are crucial for airway homeostasis and protection from extrinsic 
pollutants (189). Our results demonstrate a higher reactivity in IPF and nLS patients as 
compared to healthy controls and LS patients. This coincides with previous findings of 
increased anti-ZNF688 in sarcoidosis patients, though to our knowledge, ZNF688 has not 
previously been associated with IPF.  
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In contrast to ZNF688, COL5A1 has been implicated in numerous diseases and conditions, 
most notably Ehlers-Danlos syndrome (207) and adenocarcinoma metastasis (208). 
Furthermore, autoimmunity towards COL5A1 is suspected to play an important role in 
pulmonary transplant rejection and the occurrence of bronchiolitis obliterans (BOS) (162, 
209). The HLA-DRB1*15 allele was overrepresented in a cohort of IPF patients who had 
undergone transplant, in addition, an association between HLA-DRB1*15 and COL5A1 
autoantibodies was detected in pre-transplant IPF patients (162, 210, 211). This supports 
our findings where IPF patients demonstrated a significant higher frequency of 
autoantibodies against COL5A1. The connection to HLA-DRB1*15 is interesting since it links 
to sarcoidosis where the HLA variant corresponds to a worse prognosis and thus higher 
likelihood of fibrosis (1). With this in regard, it provides the possibility that early detection of 
autoantibodies against COL5A1 in patients with HLA-DRB1*15 could foreshadow future 
fibrosis development in IPF and/or sarcoidosis.  
In our peptide analysis of the COL5A1 protein fragments, some heterogeneity was apparent; 
however there were clear overlaps where several peptides were present across all cohorts 
in both BAL and serum (Figure 19A-F). Potential cross-reactivity and genetic/social variability 
could explain the variations, however all IPF and nLS cohorts displayed reactivity to peptides 
within the COL5A1 fragment, further highlighting the potential of autoreactivity against 
COL5A1 in fibrosis development.  
Autoantigens were found in a majority of patient samples, including healthy controls, 
although that cohort displayed a lower frequency of autoreactivity and also relatively lower 
titers. Altogether, autoreactivity was higher in IPF and in nLS patients compared to all other 
groups; both groups include a higher fibrosis rate than the other diseases potentially linking 
autoreactivity to fibrosis development. The protein epitope of COL5A1 is proposed as an 
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11 CONCLUSIONS 
In this thesis we have investigated the autoreactive range of antigens and antibodies in 
patients with sarcoidosis and IPF as well as control subjects, as well as various different 
control diseases. We discovered several autoreactive targets with potential autoimmune 
effects. Many of the targets have been present in both BAL and serum which provide a 
possibility of finding a marker that can monitor its disease from a blood sample, which 
would be beneficial and more comfortable for the patient.  
Project I, II and IV can be categorized as semi-targeted, since the main feature is to generate 
interesting targets for further studies, but utilize a top-down approach where we select the 
proteins and antibodies that we are investigating. This generates a vast amount of data and 
the most difficult part is to decipher which target or what result actually matter and is not 
just an epiphenomenon. This is similar to a game of Tetris, where one has to figure out 
where all the pieces fit. 
The main conclusions from this thesis are therefore; 
- The immunopeptidomic profiles in BAL differs between sarcoidosis patients 
and control subjects. 
- Non-Löfgren patients generally have a higher titer of autoantibodies than 
patients with löfgren syndrome.  
- In comparison to controls, ZNF688 and ARFGAP1 displayed with significantly 
higher frequency of reactivity in sarcoidosis patients.  
- Based on the results of project III we suggest that the Fc galactosylation 
status of IgG4 could potentially be used a serum marker for level of 
inflammation in lung disease.  
- With regard to autoantibody profiles, Non-Löfgren patients are more similar 
to IPF patients, rather than Löfgren syndrome patients. 
- The protein epitope of COL5A1 is proposed as an autoreactive target and/or 
marker of fibrosis in IPF and non-Löfgren sarcoidosis, and is of interest for 
further investigation.  
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12 POINTS OF PERSPECTIVE 
By investigating samples from IPF, sarcoidosis and controls we will gather a repertoire of 
autoantibodies displaying reactivity for each disease as well for healthy subjects. Both the 
mSBA analyses as well as the IgG-OMICS approach has revealed potential 
antigens/autoantibodies, however to test their function further studies need to be 
conducted. We collaborate with Professor Andrew Fontenot (University of Colorado) to 
generate hybridomas expressing TCRs of interest, i.e. identical TCRs of lung T cells of 
different patients. These hybridomas are produced to recognize peptides presented on the 
DRB1*03 molecule. T cell hybridomas will be used for screening a peptide library. Our 
studies may result in the identification of disease markers that could be suitable targets for 
immunotherapy and/or serve as disease markers.  
It is also possible to use T-cell hybridomas as well as BAL cells expressing VA2.3+ peptides on 
TCRs, in stimulate by the candidate antigens as identified in our previous studies. Cytokine 
production and proliferative capacity will be analyzed by Fluorospot/Flow cytometry. 
We intend to test if the identified protein targets are able to stimulate T-cells from the 
disease groups. One approach is to take antigens such as vimentin, ZNF688 or Col5A1 from 
patients with IPF or sarcoidosis and analyze on ELISpot in order to understand if generated 
autoantibodies and their corresponding autoantigen can stimulate production of, for 
example, interferon gamma as an indication that the antigen can elicit a function. 
Particularly Vimentin since such autoantibodies has been described for both IPF and 
sarcoidosis, in addition to COL5A1 which could benefit both disease groups if properly 
associated to fibrosis.  
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